Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for weight loss in obese type 2 diabetic hemodialysis patients
2020-000043-31Phase 2Completed
- Sponsor
- Groupe hospitalier Paris Saint-Joseph
- Start
- Jan 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liraglutide in type 2 diabetes mellitus (T2DM), obesity and end-stage kidney disease (ESKD), sponsored by Groupe hospitalier Paris Saint-Joseph. Primary endpoint: Weight loss at 6 months. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesityend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2020-000043-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000043-31.